We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Broadridge to Benefit From FundsLibrary Buyout: Here's How
Read MoreHide Full Article
Broadridge Financial Solutions, Inc.(BR - Free Report) yesterday announced that it has completed the acquisition of FundsLibrary — a leader in fund document and data dissemination in the European market — from Hargreaves Lansdown. The deal was initially announced on Jan 21, 2020. Financial terms have been kept under wraps.
Over the past year, shares of Broadridge have gained 6.6% against 1.2% decline of the industry it belongs and 4.9% rally of the Zacks S&P 500 composite.
Ramp Up of European Regulatory Communications Business
FundsLibrary will be merged with FundAssist, Broadridge's existing European funds regulatory communications business.
The union of FundsLibrary's data platform and technology with Broadridge's existing fund calculation, document creation and translation capabilities should help fund managers increase distribution opportunities and comply with both UK domestic and EU regulations such as Solvency II and MiFID II.
The combined entity will be known as Broadridge Fund Communication Solutions, and will be led by Arun Sarwal, former CEO of FundsLibrary.
Collectively, the buyout will amplify Broadridge's pan-European regulatory communications and digital data platform, supporting the lifecycle of fund data, documents, and regulatory reporting for the investment industry.
Considering the increasing demand for regulatory requirements across multiple jurisdictions, the deal seems to be a strategic move on Broadridge's part to strengthen its foothold in the global investment industry.
We also believe the move will help Broadridge strengthen its Investor Communication Solutions segment, which offers governance and communications solutions to banks/broker-dealers, asset management firms/mutual funds, corporate issuers and wealth management firms. Revenues from the segment decreased 2% year over year in second-quarter fiscal 2020.
Zacks Rank & Stocks to Consider
Currently, Broadridge carries a Zacks Rank #4 (Sell).
Long-term expected EPS (three to five years) growth rate for Interpublic, Omnicom and Genpact is 4.5%, 5.6% and 11.9%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Broadridge to Benefit From FundsLibrary Buyout: Here's How
Broadridge Financial Solutions, Inc.(BR - Free Report) yesterday announced that it has completed the acquisition of FundsLibrary — a leader in fund document and data dissemination in the European market — from Hargreaves Lansdown. The deal was initially announced on Jan 21, 2020. Financial terms have been kept under wraps.
Over the past year, shares of Broadridge have gained 6.6% against 1.2% decline of the industry it belongs and 4.9% rally of the Zacks S&P 500 composite.
Ramp Up of European Regulatory Communications Business
FundsLibrary will be merged with FundAssist, Broadridge's existing European funds regulatory communications business.
The union of FundsLibrary's data platform and technology with Broadridge's existing fund calculation, document creation and translation capabilities should help fund managers increase distribution opportunities and comply with both UK domestic and EU regulations such as Solvency II and MiFID II.
The combined entity will be known as Broadridge Fund Communication Solutions, and will be led by Arun Sarwal, former CEO of FundsLibrary.
Collectively, the buyout will amplify Broadridge's pan-European regulatory communications and digital data platform, supporting the lifecycle of fund data, documents, and regulatory reporting for the investment industry.
Considering the increasing demand for regulatory requirements across multiple jurisdictions, the deal seems to be a strategic move on Broadridge's part to strengthen its foothold in the global investment industry.
We also believe the move will help Broadridge strengthen its Investor Communication Solutions segment, which offers governance and communications solutions to banks/broker-dealers, asset management firms/mutual funds, corporate issuers and wealth management firms. Revenues from the segment decreased 2% year over year in second-quarter fiscal 2020.
Zacks Rank & Stocks to Consider
Currently, Broadridge carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader Zacks Business Services sector are Interpublic (IPG - Free Report) , Omnicom (OMC - Free Report) and Genpact (G - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Long-term expected EPS (three to five years) growth rate for Interpublic, Omnicom and Genpact is 4.5%, 5.6% and 11.9%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>